fleroxacin has been researched along with amoxicillin in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (22.22) | 18.7374 |
| 1990's | 7 (38.89) | 18.2507 |
| 2000's | 3 (16.67) | 29.6817 |
| 2010's | 4 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Altwegg, M; Hohl, P; Lüthy-Hottenstein, J; Zollinger-Iten, J | 1 |
| Claeys, G; Van den Abeele, AM; Verschraegen, G | 1 |
| Andrews, JM; Ashby, JP; Matthews, RS; Wise, R | 1 |
| Adamis, G; Gargalianos, P; Kosmidis, J; Makris, D; Petropoulou, D | 1 |
| Crokaert, F; Glupczynski, Y; Lismont, MJ; Van der Linden, MP; Yourassowsky, E | 1 |
| Chodosh, S | 1 |
| Ulmer, W | 1 |
| Nichols, RL; Smith, JW | 1 |
| Powers, RD | 1 |
| Tassler, H | 1 |
| Brown, P; Rana, C; Silagy, C; Whitby, M | 1 |
7 trial(s) available for fleroxacin and amoxicillin
| Article | Year |
|---|---|
Fleroxacin in single dose oral therapy of uncomplicated lower urinary tract infection.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Amoxicillin; Anti-Infective Agents; Ciprofloxacin; Escherichia coli; Female; Fleroxacin; Humans; Middle Aged; Proteus mirabilis; Random Allocation; Staphylococcus aureus; Urinary Tract Infections | 1988 |
Efficacy of fleroxacin versus amoxicillin in acute exacerbations of chronic bronchitis.
Topics: Acute Disease; Aged; Amoxicillin; Bacteria; Bacterial Infections; Bronchitis; Chronic Disease; Confidence Intervals; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Microbial; Female; Fleroxacin; Humans; Male; Middle Aged | 1993 |
Fleroxacin versus amoxicillin in the treatment of acute exacerbation of chronic bronchitis.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Amoxicillin; Bacteria; Bronchitis; Chronic Disease; Double-Blind Method; Female; Fleroxacin; Humans; Male; Middle Aged; Prospective Studies; Superinfection; Treatment Outcome | 1993 |
Comparison of oral fleroxacin with oral amoxicillin/clavulanate for treatment of skin and soft tissue infections.
Topics: Administration, Oral; Adolescent; Adult; Aged; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Bacteria; Bacterial Infections; Chi-Square Distribution; Clavulanic Acids; Double-Blind Method; Drug Therapy, Combination; Female; Fleroxacin; Humans; Male; Middle Aged; Skin Diseases, Bacterial; Treatment Outcome | 1993 |
Open trial of oral fleroxacin versus amoxicillin/clavulanate in the treatment of infections of skin and soft tissue.
Topics: Administration, Oral; Adolescent; Adult; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Bacterial Infections; Clavulanic Acids; Drug Therapy, Combination; Fleroxacin; Humans; Prospective Studies; Skin Diseases, Bacterial; Treatment Outcome | 1993 |
Comparative efficacy and safety of oral fleroxacin and amoxicillin/clavulanate potassium in skin and soft tissue infections.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Bacteria; Bacterial Infections; Clavulanic Acids; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Fleroxacin; Humans; Male; Middle Aged; Prospective Studies; Skin Diseases, Bacterial | 1993 |
Comparison of fleroxacin and amoxicillin in the treatment of uncomplicated urinary tract infections in women.
Topics: Adolescent; Adult; Amoxicillin; Female; Fleroxacin; Humans; Treatment Outcome; Urinary Tract Infections | 1993 |
11 other study(ies) available for fleroxacin and amoxicillin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
In vitro activities of fleroxacin, cefetamet, ciprofloxacin, ceftriaxone, trimethoprim-sulfamethoxazole, and amoxicillin-clavulanic acid against rare members of the family Enterobacteriaceae primarily of human (clinical) origin.
Topics: Amoxicillin; Anti-Bacterial Agents; Ceftizoxime; Ceftriaxone; Ciprofloxacin; Clavulanic Acid; Clavulanic Acids; Enterobacteriaceae; Enterobacteriaceae Infections; Fleroxacin; Humans; Microbial Sensitivity Tests; Trimethoprim, Sulfamethoxazole Drug Combination | 1990 |
Comparative in vitro activity of the new quinolone fleroxacin (RO 23-6240).
Topics: Amikacin; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacteria; Cefaclor; Ceftazidime; Cefuroxime; Ciprofloxacin; Clavulanic Acids; Corynebacterium; Drug Combinations; Drug Resistance, Microbial; Fleroxacin; Norfloxacin; Pefloxacin; Piperacillin; Staphylococcus; Vancomycin | 1988 |
In vitro activity of lomefloxacin, a new quinolone antimicrobial agent, in comparison with those of other agents.
Topics: Amoxicillin; Anti-Bacterial Agents; Bacteria; Blood Proteins; Cefuroxime; Ciprofloxacin; Enterobacteriaceae; Fleroxacin; Fluoroquinolones; Haemophilus influenzae; Humans; Ofloxacin; Oxazines; Protein Binding; Pseudomonas aeruginosa; Quinolines; Quinolones; Staphylococcus; Streptococcus; Trimethoprim | 1988 |
Rate of bactericidal activity for Branhamella catarrhalis of fleroxacin compared with that of amoxycillin-clavulanic acid.
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Ciprofloxacin; Clavulanic Acids; Culture Media; Drug Therapy, Combination; Fleroxacin; Microbial Sensitivity Tests; Moraxella catarrhalis | 1988 |